The Indonesian Journal of Infectious Diseases最新文献_第3页

Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada 加拿大安大略省长期护理居民第四剂COVID-19 mRNA疫苗的有效性和保护时间

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-30 DOI: 10.1101/2022.09.29.22280526

R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong

{"title":"Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada","authors":"R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong","doi":"10.1101/2022.09.29.22280526","DOIUrl":"https://doi.org/10.1101/2022.09.29.22280526","url":null,"abstract":"Background: As of December 30, 2021, Ontario long-term care (LTC) residents who received a third dose of COVID-19 vaccine [≥]84 days previously were offered a fourth dose to prevent a surge in COVID-19-related morbidity and mortality due to the Omicron variant. Seven months have passed since fourth doses were implemented, allowing for the examination of fourth dose protection over time. Methods: We used a test-negative design and linked databases to estimate the marginal effectiveness (4 versus 3 doses) and vaccine effectiveness (VE; 2, 3, or 4 doses versus no doses) of mRNA vaccines among Ontario LTC residents aged [≥]60 years who were tested for SARS-CoV-2 between December 30, 2021 and August 3, 2022. Outcome measures included any Omicron infection, symptomatic infection, and severe outcomes (hospitalization or death). Results: We included 21,275 Omicron cases and 273,466 test-negative controls. The marginal effectiveness of a fourth dose <84 days ago compared to a third dose received [≥]84 days ago was 23% (95% Confidence Interval [CI] 17-29%), 36% (95%CI 26-44%), and 37% (95%CI 24-48%) against SARS-CoV-2 infection, symptomatic infection, and severe outcomes, respectively. Additional protection provided by a fourth dose compared to a third dose was negligible against all outcomes [≥]168 days after vaccination. Compared to unvaccinated individuals, vaccine effectiveness (VE) of a fourth dose decreased from 49% (95%CI 44%-54%) to 18% (95%CI 5-28%) against infection, 69% (95%CI 62-75%) to 44% (95%CI 24-59%) against symptomatic infection, and 82% (95%CI 77-86%) to 74% (95%CI 62-82%) against severe outcomes <84 days versus [≥]168 days after vaccination. Conclusions: Our findings suggest that fourth doses of mRNA COVID-19 vaccines provide additional protection against Omicron-related outcomes in LTC residents, but the protection wanes over time, with more waning seen against infection than severe outcomes.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90573292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso Sulianti Saroso博士的儿童RSPI的肺结核概要

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.134

Agatha Nagrintya Ginting, Kriston Silitonga, Suliati Suliati, Farida Murtiani

{"title":"Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso","authors":"Agatha Nagrintya Ginting, Kriston Silitonga, Suliati Suliati, Farida Murtiani","doi":"10.32667/ijid.v8i1.134","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.134","url":null,"abstract":"Latar belakang: Tuberkulosis (TB) adalah penyakit infeksi menular yang disebabkan oleh Mycobacterium tuberculosis (MTB) dan salah satu dari 10 penyebab kematian di dunia, 11% kasus diantaranya adalah anak-anak. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui karakteristik, manifestasi klinis, gambaran riwayat kesehatan pasien, pengobatan, dan efek samping obat tuberculosis anak. Metode: Penelitian deskriptif. Data bersumber dari rekam medik dan form TB 01 periode Januari-Desember 2018. Hasil: Mayoritas pasien adalah anak laki-laki berusia 1-4 tahun. Manifestasi klinis batuk ditemukan sebanyak 71,8%; demam 53,8%; pembesaran KGB 43,6%; dan penurunan berat badan 33,3%. Sebagian besar (84,6%) tidak ada riwayat kontak dengan penderita TB dan 30.8% sudah mendapatkan imunisasi BCG. Sebanyak 46.2% memiliki hasil uji tuberculin positif dan hasil foto gambaran khas TB pada foto thorax. Berdasarkan riwayat kesehatan, 46.2% di antaranya bergizi baik, 89.7% merupakan pasien baru dan hanya 15 anak dengan penyakit penyerta. Pada studi ini, sebagian besar (82,1%) mendapatkan Obat Anti Tuberkulosis (OAT) anak, dengan kombinasi obat HRZ pada tahap intensif 61,5% dengan lama pengobatan 6 bulan sebanyak 48,7%. Kesimpulan: Terdapat variasi spektrum klinis yang luas pada TB anak dengan pengobatan OAT.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81612116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hubungan Antara Kadar Vitamin D dengan Derajat Keparahan COVID-19

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.130

Handoko Handoko, Angki Purwanti, Dian Wahyu Tanjungsari, I. Pertiwi, Farida Murtiani

引用次数: 0

Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.135

H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani

{"title":"Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan","authors":"H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani","doi":"10.32667/ijid.v8i1.135","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.135","url":null,"abstract":"Latar Belakang:. Penyakit Coronavirus 2019 merupakan penyakit sistem pernapasan yang baru saja muncul dan menjadi pandemi. Indonesia mengalami peningkatan jumlah kasus yang cukup drastis. Derajat keparahan yang dialami oleh pasien COVID-19 dapat dipengaruhi oleh berbagai hal seperti usia, penyakit komorbid, defisiensi vitamin D, dan obesitas. Penelitian ini bertujuan untuk mengetahui hubungan jumlah komorbid dan derajat keparahan terhadap kematian pada pasien COVID-19. Metode: Penelitian deskriptif analitik dengan rancangan cross sectional. Total sampel 1240 pasien COVID-19 RSPI Sulianti Saroso Tahun 2020 2021. Hasil: Komorbid terbanyak adalah hipertensi dan diabetes melitus, derajat keparahan kategori sedang dan outcome hidup. Hasil analisis ada hubungan antara jumlah komorbid dengan status kematian (OR=1,585). Ada hubungan diabetes melitus dengan status kematian pasien pada pasien COVID-19 (OR=1,927). Ada hubungan antara derajat keparahan dengan status kematian pada pasien COVID-19 (OR=12,699). Kesimpulan: Derajat keparahan, jumlah komorbid dan komorbid diabetes mellitus berhubungan merupakan faktor risiko kematian pada pasien COVID-19.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87532605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Penerapan Posisi Pronasi Terhadap Peningkatan Oksigenasi Pada Pasien COVID-19 Dengan Pneumonia 采用新式位置，以提高19号住院病人的氧化水平和肺炎为例

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.133

D. Kurniasih, Fitrian Rayasari, Ahmad Zubairi, S. Suryati, Kunti Wijiarti, Farida Murtiani

引用次数: 0

Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.132

Sriyanto Sriyato, Lyana Setiawan, Rizana Fajrunni’mah, Farida Murtiani

{"title":"Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19","authors":"Sriyanto Sriyato, Lyana Setiawan, Rizana Fajrunni’mah, Farida Murtiani","doi":"10.32667/ijid.v8i1.132","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.132","url":null,"abstract":"Latar belakang: COVID-19 menjadi masalah kesehatan di dunia. Penanda inflamasi yang dapat digunakan sebagai predictor prognosis COVID-19 salah satunya Interlukin-6 (IL-6) dan Neutrofil Lymphocyte Ratio (NLR). Tujuan penelitian: mengetahui hubungan kadar IL-6 dengan NLR pada pasien COVID-19. Metode: Penelitian kuantitatif dengan desain cross sectional. Data yang dikumpulkan dari rekam medik pasien COVID-19 di RS Kanker Dharmais periode Januari-Juli 2021. Jumlah sampel sebanyak 70 pasien yang memenuhi kriteria inklusi dan eksklusi. Analisa data dilakukan secara univariat dan bivariat dengan korelasi spearman. Hasil: Dari 70 pasien COVID-19 sebagian besar berusia dalam kategori lansia akhir (56-65 Tahun) 17 (24,3%) dan jenis kelamin sebagian besar laki-laki yaitu 42 (60%). Rata-rata kadar IL-6 43,34 pg/ml dan rata-rata NLR 12,73. Ada korelasi antara kadar IL-6 dengan NLR pada pasien COVID-19 (P Value=0,000; nilai r 0.563). Kesimpulan: Adanya korelasi positif IL-6 dengan NLR. IL-6 adalah salah satu biomarker yang digunakan untuk memprediksi prognosis COVID-19 karena pemeriksaannya yg kompleks, tidak dapat memprosesnya di lab yg sederhana. Sebagai gantinya, kami menyimpulkan pemeriksaan NLR dapat menjadi biomarker alternatif. ","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75892757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 在先前接受过两剂灭活疫苗的成年人中，第三剂BNT162b2后抗体缓慢减弱

The Indonesian Journal of Infectious Diseases Pub Date : 2022-07-18 DOI: 10.1101/2022.07.18.22277741

B. Cowling, S. Cheng, M. Martín-Sánchez, N. Y. M. Au, K. Chan, John K. C. Li, Lison W C Fung, L. Luk, L. Tsang, D. Ip, Leo L. M. Poon, G. Leung, J. Peiris, N. Leung

{"title":"Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine","authors":"B. Cowling, S. Cheng, M. Martín-Sánchez, N. Y. M. Au, K. Chan, John K. C. Li, Lison W C Fung, L. Luk, L. Tsang, D. Ip, Leo L. M. Poon, G. Leung, J. Peiris, N. Leung","doi":"10.1101/2022.07.18.22277741","DOIUrl":"https://doi.org/10.1101/2022.07.18.22277741","url":null,"abstract":"Introduction: Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. Methods: We administered BNT162b2 as a third dose to adults aged [≥]30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2. Results: We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity. Conclusions: While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73918906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Indonesian Journal of Infectious Diseases Pub Date : 2022-06-17 DOI: 10.1093/infdis/jiac248

A. Gómez-Carballa, S. Pischedda, I. Rivero-Calle, J. Montoto-Louzao, F. Martinon-Torres, A. Salas

引用次数: 0

Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands 与荷兰检测阴性和人口控制相比，感染SARS-CoV-2后3个月的患病率和症状严重程度

The Indonesian Journal of Infectious Diseases Pub Date : 2022-06-16 DOI: 10.1101/2022.06.15.22276439

T. van der Maaden, Elizabeth N Mutubuki, S. de Bruijn, K. Y. Leung, H. Knoop, Jaap Slootweg, A. D. Tulen, A. Wong, A. V. van Hoek, E. Franz, C. C. van den Wijngaard

{"title":"Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands","authors":"T. van der Maaden, Elizabeth N Mutubuki, S. de Bruijn, K. Y. Leung, H. Knoop, Jaap Slootweg, A. D. Tulen, A. Wong, A. V. van Hoek, E. Franz, C. C. van den Wijngaard","doi":"10.1101/2022.06.15.22276439","DOIUrl":"https://doi.org/10.1101/2022.06.15.22276439","url":null,"abstract":"Background: More information is needed on prevalence of long-term symptoms after SARS-CoV-2-infection. This prospective study assesses symptoms three months after SARS-CoV-2-infection compared to test-negative and population controls, and the effect of vaccination prior to infection. Methods: Participants enrolled after a positive (cases) or negative (test-negative controls) SARS-CoV-2-test, or after invitation from the general population (population controls). After three months, participants indicated presence of 41 symptoms, and severity of four symptoms. Permutation tests were used to select symptoms significantly elevated in cases compared to controls and to compare symptoms between cases that were vaccinated or unvaccinated prior to infection. Findings: Between May 19th and December 13th 2021 9166 cases, 1698 symptomatic but test-negative controls, and 3708 population controls enrolled. At three months, 13 symptoms, and severity of fatigue, cognitive impairment and dyspnoea, were significantly elevated between cases and controls. Of cases, 48.5% reported [≥]1 significantly elevated symptom, compared to 29.8% of test-negative controls and 26.0% of population controls. Effect of vaccination could only be determined for cases <65yrs, and was found to be significantly protective for loss of smell and taste but not for other symptoms. Interpretation: Three months after SARS-CoV-2 infection, almost half of the cases still report symptoms, which is higher than the background prevalence and prevalence in test-negative controls. Vaccination prior to infection was protective against loss of smell and taste as assessed in cases aged <65.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91326539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia 刚果民主共和国和亚洲青蒿素治疗疗效研究中抗体反应和寄生虫清除的比较

The Indonesian Journal of Infectious Diseases Pub Date : 2022-06-15 DOI: 10.1093/infdis/jiac232

J. Cutts, Katherine O’Flaherty, S. Zaloumis, E. Ashley, Jo-Anne Chan, M. Onyamboko, Caterina A Fanello, A. Dondorp, Nicholas P J Day, A. Phyo, M. Dhorda, M. Imwong, R. Fairhurst, Pharath Lim, C. Amaratunga, S. Pukrittayakamee, T. Hien, Y. Htut, M. Mayxay, M. Faiz, E. Takashima, T. Tsuboi, J. Beeson, F. Nosten, J. Simpson, N. White, F. Fowkes

{"title":"Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia","authors":"J. Cutts, Katherine O’Flaherty, S. Zaloumis, E. Ashley, Jo-Anne Chan, M. Onyamboko, Caterina A Fanello, A. Dondorp, Nicholas P J Day, A. Phyo, M. Dhorda, M. Imwong, R. Fairhurst, Pharath Lim, C. Amaratunga, S. Pukrittayakamee, T. Hien, Y. Htut, M. Mayxay, M. Faiz, E. Takashima, T. Tsuboi, J. Beeson, F. Nosten, J. Simpson, N. White, F. Fowkes","doi":"10.1093/infdis/jiac232","DOIUrl":"https://doi.org/10.1093/infdis/jiac232","url":null,"abstract":"Abstract Background Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"65 1","pages":"324 - 331"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85800569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1